Onyia Jude reported option exercise involving 11,000 derivative units of NEUROCRINE BIOSCIENCES INC at $0.00 for $0 on May 27, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Scientific Officer
Chief Scientific Officer
Filed May 29, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
11,000Non-Qualified Stock Option
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
24,268Direct
Trade date
May 27, 2026Option exercise
Filed
May 29, 2026, 6:09 PM ET2-day reporting delay
Accession
0001894425-26-000010Code M · Transaction 94755
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 27, 2026Option exercise11,000$84.74$932,140Trade 94753
May 27, 2026Sell11,000$155.53−$1,710,865.20Trade 94754
3 transaction rows in this filing. Joint filers share the same rows.

NBIX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NBIX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −19%1w ago −2.3%1d ago −1.6%
Returns since7d +3.5%30d +6.5%90d180d1y

Footnotes in full

F1: Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. F2: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $154.47 to $156.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4: Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.